Memorial Sloan Kettering Cancer Center (MSK) is collaborating with Triomics, an oncology-focused generative artificial intelligence company, to deploy Triomics’ artificial intelligence (AI)-powered clinical trial matching and screening platform in MSK’s active clinical trials.
Triomics participated in the 2024 Cohort of MSK’s selective iHub Challenge program and has now joined the MSK Innovation Hub (iHub). The MSK Clinical Research Innovation Consortium (CRIC) and MSK iHub teams plan to roll out Triomics’ AI-powered system in two phases, with a view to encompassing the full portfolio of MSK clinical trials.
Manually pre-screening medical records against an extensive clinical trial portfolio can take up to 45 minutes per patient, especially when the records include clinician notes and PDFs. The Triomics AI-powered platform automatically analyzes patient records, identifies eligible trials, and provides an itemized rationale with source citations, enabling clinical research teams to recruit trial participants much faster and with greater confidence.
“Real-time, evidence-linked matching transforms clinical trial screening from a bottleneck to an efficient, streamlined process,” said Joe Lengfellner, Senior Director, Clinical Research Informatics & Technology at MSK. “This collaboration will enable our teams to surface opportunities that might otherwise be missed, allowing us to offer trials to more patients.”
“Collaborating with MSK represents a significant milestone. MSK’s leadership in clinical research and innovation makes it an ideal partner as we work together to demonstrate how generative AI can transform oncology trial operations and accelerate access to cutting-edge therapies,” said Sarim Khan, Triomics’ Co-Founder and CEO.
MSK’s earlier work with Triomics through the 2024 iHub Challenge Cohort program has helped jumpstart this expanding relationship. “Working with MSK through the iHub Challenge gave us direct access to senior research and innovation leaders, allowing the team to validate our technology quickly and accelerate implementation. That collaboration meaningfully shortened the path from pilot to deployment, helping us move into the broader partnership with confidence and shared momentum,” noted Sebastien Rhodes, VP of Strategy & Operations at Triomics.
As part of the collaboration, Paul Sabbatini, Senior Vice President for Clinical Research at MSK, will join Triomics’ Customer Advisory Board, which helps guide the responsible scale-up of the platform across Triomics’ network of partner cancer centers.
MSK has institutional financial interests related to Triomics.
For more on MSK’s collaboration with Triomics, see here.